Tango Therapeutics, Inc.
TNGX
Positions held
Your positionsTNGX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Tango Therapeutics is positioned in the biotechnology sector, focusing on innovative therapies that target cancer, which is a growing area of investment due to increasing global healthcare needs.
- In Q3 2025, Tango Therapeutics reported an operating margin of 26.2%, indicating potential for profitability as they scale operations.
- The company's market cap stands at approximately $3.69 billion, reflecting investor confidence despite current challenges.
- Tango Therapeutics has a strong sell signal with a score of -23.00, indicating significant bearish sentiment among analysts.
- The company has reported negative net income for multiple quarters, with a net loss of $55.341 million in Q2 2026.
- Tango's debt-to-equity ratio is 3.123, suggesting high leverage and potential financial risk.
Fundamentals
| Market cap | $3.81B | Enterprise value | $2.82B | Trailing P/E | — | Forward P/E | -13.39 |
| PEG | — | Price / book | 8.31 | Beta | 1.17 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | -148.4% | Operating margin | -2.5% |
| Profit margin | -2.3% | ROE | -21.3% | ROA | -13.0% | Debt / equity | 0.03 |
| Current ratio | 50.82 | Free cash flow | -$71.87M | Analyst recommendation | strong_buy | Mean target | $45.18 |
| 52w high | $34.39 | 52w low | $6.69 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $53.8M | $3.2M |
| Op margin | — | — | — | 26.2% | -1287.9% |
| Net income | -$55.3M | -$45.5M | -$38.7M | $15.9M | -$38.9M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$59.8M | -$48.8M | -$41.9M | $14.1M | -$41.0M |
- Operating margin expanded to 26.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M |
| Op margin | -178.4% | -346.1% | -312.6% | -446.8% |
| Net income | -$102M | -$130M | -$102M | -$108M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$111M | -$146M | -$114M | -$111M |
Headlines — watch
• [WARN · fundamentals] TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
News
2026-10-05 · Tango Therapeutics Insider Sold Shares Worth $660,796, According to a Recent SEC Filing
2026-09-10 · Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
2026-09-04 · Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey
2026-09-03 · Tango Therapeutics Insider Sold Shares Worth $603,909, According to a Recent SEC Filing
2026-09-03 · Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 · Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
2026-08-27 · RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer
2026-08-12 · TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
2026-08-11 · Tango Therapeutics Q2 Net Loss Widens
2026-08-11 · Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
2026-08-07 · Tango Therapeutics Executive Chair Barbara Weber Departs
2026-08-06 · Tango Therapeutics Announces Executive Chair Transition
Price (daily)
Full chart · RSI · MACD · patterns